Guardians at the gate: Patent protection for therapeutic monoclonal antibodies—part 1

AUTOR(ES)

McCabe, Kevin W

FONTE

Landes Bioscience

RESUMO

Patents provide one of the few protections companies can avail themselves of to help protect their therapeutic monoclonal antibody products. Just as the therapeutic monoclonal antibody field is constantly evolving, so too is the legal environment surrounding these inventions. In a series of articles, the general state of the law surrounding therapeutic antibodies will be explained, and important challenges to this technology area will be discussed. Much is at stake when companies market therapeutic monoclonal antibodies; therefore, a firm understanding of this important form of protection is critically important for anyone developing such products.

Documentos Relacionados

• Guardians at the gate: Biosimilar and patent reform legislation could fundamentally change the guards for therapeutic monoclonal antibodies—Part 2
• The fluorescence resonance energy transfer (FRET) gate: A time-resolved study
• Therapeutic monoclonal antibodies in oncology
• Synergistic Protection of Mice against Plague with Monoclonal Antibodies Specific for the F1 and V Antigens of Yersinia pestis
• Advances and challenges in therapeutic monoclonal antibodies drug development